Drug Profile
Pegargiminase - Polaris Pharmaceuticals
Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Pegylated arginine deiminase - Polaris GroupLatest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Phoenix Pharmacologics
- Developer Barts and The London School of Medicine and Dentistry; Memorial Sloan-Kettering Cancer Center; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
- Class Antineoplastics; Hepatoprotectants; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
- Mechanism of Action Arginine deiminase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Malignant-mesothelioma
- Phase III Leiomyosarcoma; Liver cancer; Soft tissue sarcoma
- Phase II/III Glioblastoma
- Phase II Acute myeloid leukaemia; Malignant melanoma; Non-alcoholic steatohepatitis; Non-Hodgkin's lymphoma; Small cell lung cancer
- Phase I Head and neck cancer
- No development reported Bladder cancer; Breast cancer; Cancer; Gastrointestinal cancer; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uveal melanoma; Viral infections
Most Recent Events
- 22 Dec 2023 Pegargiminase - Polaris Pharmaceuticals is available for licensing as of 22 Dec 2023. https://polarispharma.com/about-us/?lang=en
- 30 Nov 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in Taiwan (IM, Injection) (NCT05842512)
- 29 Nov 2023 Phase-III clinical trials in Leiomyosarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT05712694)